vai al contenuto della pagina vai al menu di navigazione

21 May - "Alzheimer’s disease and Down syndrome: implications of the shared neuropathology to the development of new therapeutic approaches", Lecture by Carmen Martinez-Cuè Pesini, University of Cantabria, Spain

The visit of Carmen Martinez-Cuè Pesini is organised in collaboration with Sandra Guidi from the Department of Biomedical and Neuromotor Sciences.

May 21, 2019 from 05:30 PM to 07:30 PM

Where Sala Rossa, Palazzo Marchesini, via Marsala 26, Bologna (first floor)

Add to your calendar

Alzheimer’s disease (AD), a condition that affects 45 million people in the world, is characterized by different neuropathological hallmarks and dementia. Today, the only approved pharmacological treatments for this condition have very limited efficacy and their effect are only symptomatic. In the last years, different strategies targeting the tau protein or aiming to reduce β-amyloid production, to prevent β-amyloid aggregation, or to enhance β-amyloid elimination (through active or passive immunotherapies) have been tested. Although many of them have been proven to be effective in preclinical settings, over 99 % of them have not demonstrated any efficacy or have been shown to have important adverse effects in Clinical trials. One of the reasons for this failure has been suggested to be fact that most animal models of AD, in which preclinical studies are performed, are based on genetic alterations found in different types of Familiar AD, that only accounts for 5 % of the cases of AD, which are not found in Sporadic AD (95 % of the cases). Because 100 % of individuals with Down syndrome (DS) develop AD neuropathology by their fourth decade of life, it has been proposed that Down syndrome could be a more adequate setting to study the neurobiological basis of AD and to test new therapeutic targets. This seminar will review the preclinical evidence that have led to Clinical trials that are taking place in DS and AD, with special emphasis on the new therapeutic strategies.